SpringWorks Therapeutics Quarterly Balance Sheets Chart
Quarterly
|
Annual
SpringWorks Therapeutics Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||||||
| current assets: | |||||||||||||||||||||||
| cash and cash equivalents | 63,774,000 | 69,751,000 | 84,456,000 | 79,898,000 | 118,031,000 | 176,053,000 | 98,895,000 | 115,001,000 | 102,401,000 | 67,490,000 | 476,429,000 | 69,571,000 | 81,933,000 | 103,961,000 | 93,852,000 | 84,571,000 | 95,426,000 | 147,089,000 | 84,831,000 | 226,666,000 | 311,075,000 | 327,652,000 | 343,825,000 |
| marketable securities | 224,099,000 | 238,234,000 | 292,163,000 | 303,987,000 | 318,552,000 | 303,149,000 | 323,524,000 | 361,706,000 | 425,740,000 | 524,722,000 | 175,514,000 | 264,970,000 | 266,338,000 | 269,540,000 | 334,060,000 | 378,206,000 | 381,985,000 | 361,395,000 | 191,988,000 | 64,567,000 | |||
| accounts receivable | 40,347,000 | 46,238,000 | 32,972,000 | 24,504,000 | 15,529,000 | 5,930,000 | |||||||||||||||||
| inventory | 12,417,000 | 10,212,000 | 9,826,000 | 7,718,000 | 5,216,000 | 3,103,000 | |||||||||||||||||
| prepaid expenses and other current assets | 15,683,000 | 16,030,000 | 15,694,000 | 15,217,000 | 14,470,000 | 12,677,000 | 9,964,000 | 7,194,000 | 9,516,000 | 7,548,000 | 5,344,000 | 7,458,000 | 7,680,000 | 9,409,000 | 5,101,000 | 4,214,000 | 4,103,000 | 4,914,000 | 2,083,000 | 2,563,000 | 2,567,000 | 3,709,000 | 689,000 |
| total current assets | 356,320,000 | 380,465,000 | 435,111,000 | 431,324,000 | 471,798,000 | 500,912,000 | 432,383,000 | 483,901,000 | 537,657,000 | 599,760,000 | 657,287,000 | 341,999,000 | 355,951,000 | 382,910,000 | 433,013,000 | 466,991,000 | 481,514,000 | 513,398,000 | 278,902,000 | 293,796,000 | 313,642,000 | 331,361,000 | 344,514,000 |
| long-term marketable securities | 94,783,000 | 153,933,000 | 121,504,000 | 138,048,000 | 136,404,000 | 183,386,000 | 4,794,000 | 32,475,000 | 59,230,000 | 52,731,000 | 44,706,000 | 63,631,000 | 53,336,000 | ||||||||||
| property and equipment | 19,250,000 | 19,680,000 | 19,336,000 | 18,205,000 | 18,263,000 | 17,943,000 | 20,924,000 | 18,238,000 | 15,728,000 | 13,571,000 | 11,482,000 | 9,193,000 | 6,035,000 | 3,187,000 | 2,089,000 | 1,025,000 | 1,024,000 | 1,075,000 | 1,176,000 | 1,072,000 | 885,000 | 795,000 | 820,000 |
| operating lease right-of-use assets | 6,578,000 | 6,979,000 | 6,026,000 | 6,362,000 | 5,817,000 | 6,144,000 | 6,465,000 | 6,763,000 | 6,602,000 | 4,698,000 | 4,908,000 | 5,132,000 | 5,356,000 | 1,010,000 | 1,242,000 | 1,471,000 | 1,697,000 | 1,944,000 | |||||
| equity method investment | 4,190,000 | 5,580,000 | 7,389,000 | 9,165,000 | 1,955,000 | ||||||||||||||||||
| restricted cash | 626,000 | 624,000 | 621,000 | 619,000 | 616,000 | 613,000 | 610,000 | 608,000 | 605,000 | 578,000 | 551,000 | 550,000 | 590,000 | 565,000 | 565,000 | 565,000 | 565,000 | 565,000 | 565,000 | 565,000 | 565,000 | 540,000 | |
| other assets | 27,799,000 | 21,405,000 | 20,700,000 | 15,384,000 | 14,769,000 | 14,835,000 | 3,483,000 | 3,005,000 | 2,891,000 | 2,648,000 | 2,453,000 | 2,687,000 | 2,627,000 | 2,709,000 | 2,451,000 | 2,219,000 | 2,547,000 | 2,002,000 | 1,440,000 | 1,440,000 | 1,440,000 | 1,159,000 | 2,062,000 |
| total assets | 505,356,000 | 587,276,000 | 608,878,000 | 617,331,000 | 656,832,000 | 725,788,000 | 467,654,000 | 517,329,000 | 569,197,000 | 630,242,000 | 681,554,000 | 365,919,000 | 405,580,000 | 452,494,000 | 495,275,000 | 520,428,000 | 554,588,000 | 576,191,000 | 286,100,000 | 301,020,000 | 317,408,000 | 334,831,000 | 348,395,000 |
| liabilities and stockholders’ equity | |||||||||||||||||||||||
| current liabilities: | |||||||||||||||||||||||
| accounts payable | 14,929,000 | 12,248,000 | 9,654,000 | 7,889,000 | 7,011,000 | 7,396,000 | 5,546,000 | 3,454,000 | 6,990,000 | 8,010,000 | 4,586,000 | 2,191,000 | 1,654,000 | 3,429,000 | 2,498,000 | 3,904,000 | 2,229,000 | 1,350,000 | 1,064,000 | 909,000 | 1,617,000 | 2,654,000 | 2,157,000 |
| accrued expenses | 65,639,000 | 86,012,000 | 59,733,000 | 45,653,000 | 56,273,000 | 65,569,000 | 40,332,000 | 35,281,000 | 28,687,000 | 39,242,000 | 39,289,000 | 32,212,000 | 21,257,000 | 25,378,000 | 24,344,000 | 17,858,000 | 15,256,000 | 14,885,000 | 11,304,000 | 8,265,000 | 6,595,000 | 8,953,000 | 7,682,000 |
| operating lease liabilities, current | 1,700,000 | 1,730,000 | 1,226,000 | 958,000 | 981,000 | 1,061,000 | 1,161,000 | 811,000 | 386,000 | 483,000 | 733,000 | 511,000 | 327,000 | 1,162,000 | 1,257,000 | 1,251,000 | 1,244,000 | 1,375,000 | |||||
| total current liabilities | 82,268,000 | 99,990,000 | 70,613,000 | 54,500,000 | 68,917,000 | 78,170,000 | 50,283,000 | 41,910,000 | 37,753,000 | 51,049,000 | 49,494,000 | 34,914,000 | 23,238,000 | 29,969,000 | 28,099,000 | 23,013,000 | 18,729,000 | 17,610,000 | 12,752,000 | 9,551,000 | 8,582,000 | 11,970,000 | 10,195,000 |
| operating lease liabilities, long-term | 5,693,000 | 6,182,000 | 5,684,000 | 6,101,000 | 5,581,000 | 5,996,000 | 6,170,000 | 6,796,000 | 6,664,000 | 4,768,000 | 5,000,000 | 5,271,000 | 5,538,000 | 129,000 | 367,000 | 701,000 | 1,031,000 | 1,359,000 | |||||
| total liabilities | 87,961,000 | 106,172,000 | 76,297,000 | 60,601,000 | 89,392,000 | 99,569,000 | 72,755,000 | 65,888,000 | 62,273,000 | 72,050,000 | 69,154,000 | 40,185,000 | 28,776,000 | 30,098,000 | 28,597,000 | 23,845,000 | 19,891,000 | 19,133,000 | 13,345,000 | 10,146,000 | 9,274,000 | 12,759,000 | 11,076,000 |
| commitments and contingencies | |||||||||||||||||||||||
| stockholders’ equity: | |||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at march 31, 2025 and december 31, 2024. | |||||||||||||||||||||||
| common stock | 8,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 5,000 | 4,000 | 4,000 | 4,000 | 4,000 | |
| additional paid-in capital | 1,678,745,000 | 1,646,537,000 | 1,618,891,000 | 1,591,138,000 | 1,560,603,000 | 1,524,196,000 | 1,199,806,000 | 1,176,686,000 | 1,153,702,000 | 1,130,224,000 | 1,111,002,000 | 752,041,000 | 733,477,000 | 715,216,000 | 703,090,000 | 691,953,000 | 683,029,000 | 675,615,000 | 402,601,000 | 399,130,000 | 396,453,000 | 395,097,000 | 394,127,000 |
| accumulated deficit | -1,236,352,000 | -1,153,165,000 | -1,075,868,000 | -1,022,338,000 | -982,419,000 | -895,034,000 | -800,712,000 | -721,275,000 | -643,350,000 | -569,930,000 | -495,752,000 | -423,364,000 | -354,314,000 | -292,513,000 | -236,441,000 | -195,400,000 | -148,390,000 | -118,603,000 | -129,875,000 | -108,216,000 | -88,323,000 | -73,029,000 | -56,812,000 |
| treasury stock | -25,448,000 | -12,579,000 | -12,056,000 | -11,557,000 | -10,638,000 | -4,141,000 | -3,888,000 | -3,624,000 | -3,272,000 | -1,341,000 | -1,341,000 | -1,129,000 | -906,000 | ||||||||||
| accumulated other comprehensive income | 442,000 | 304,000 | 1,607,000 | -520,000 | -113,000 | 1,191,000 | -312,000 | 24,000 | 25,000 | 53,000 | 41,000 | 25,000 | -44,000 | ||||||||||
| total stockholders’ equity | 417,395,000 | 481,104,000 | 532,581,000 | 556,730,000 | 567,440,000 | 626,219,000 | 394,899,000 | 451,441,000 | 506,924,000 | 558,192,000 | 612,400,000 | 325,734,000 | 376,804,000 | 422,396,000 | 466,678,000 | 496,583,000 | 534,697,000 | 557,058,000 | 272,755,000 | 290,874,000 | 308,134,000 | 322,072,000 | |
| total liabilities and stockholders’ equity | 505,356,000 | 587,276,000 | 608,878,000 | 617,331,000 | 656,832,000 | 725,788,000 | 467,654,000 | 517,329,000 | 569,197,000 | 630,242,000 | 681,554,000 | 365,919,000 | 405,580,000 | 452,494,000 | 495,275,000 | 520,428,000 | 554,588,000 | 576,191,000 | 286,100,000 | 301,020,000 | 317,408,000 | ||
| deferred revenue, current | 4,652,000 | 4,144,000 | 3,244,000 | 2,364,000 | 1,690,000 | 3,314,000 | |||||||||||||||||
| deferred revenue, long-term | 14,894,000 | 15,403,000 | 16,302,000 | 17,182,000 | 17,856,000 | 16,233,000 | |||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at december 31, 2023 and december 31, 2022. | |||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at september 30, 2024 and december 31, 2023. | |||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at june 30, 2024 and december 31, 2023. | |||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at march 31, 2024 and december 31, 2023. | |||||||||||||||||||||||
| equity investment | 3,789,000 | 4,814,000 | 5,714,000 | 4,193,000 | 4,873,000 | 6,358,000 | 2,546,000 | 2,883,000 | 3,184,000 | 3,451,000 | 3,610,000 | 3,871,000 | 4,017,000 | 4,147,000 | 876,000 | 976,000 | |||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at september 30, 2023 and december 31, 2022. | |||||||||||||||||||||||
| accumulated other comprehensive loss | -313,000 | -352,000 | -162,000 | -767,000 | -1,515,000 | -1,819,000 | -1,458,000 | ||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at june 30, 2023 and december 31, 2022. | |||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at march 31, 2023 and december 31, 2022. | |||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at december 31, 2022 and december 31, 2021. | |||||||||||||||||||||||
| other liabilities, current | 4,886,000 | ||||||||||||||||||||||
| other liabilities, long-term | 14,660,000 | ||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at september 30, 2022 and december 31, 2021. | |||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at june 30, 2022 and december 31, 2021. | |||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at march 31, 2022 and december 31, 2021. | |||||||||||||||||||||||
| other long-term liabilities | 131,000 | 131,000 | 131,000 | 164,000 | 96,000 | ||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at december 31, 2021 and december 31, 2020. | |||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at september 30, 2021 and december 31, 2020 | |||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at june 30, 2021 and december 31, 2020. | |||||||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at march 31, 2021 and december 31, 2020. | |||||||||||||||||||||||
| | |||||||||||||||||||||||
| deferred rent | 384,000 | 377,000 | 370,000 | 363,000 | 356,000 | ||||||||||||||||||
| long-term portion of deferred rent | 497,000 | 595,000 | 692,000 | 789,000 | 881,000 | ||||||||||||||||||
| preferred stock, 0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at december 31, 2020 and december 31, 2019. | |||||||||||||||||||||||
| liabilities, convertible preferred units, stock and stockholders’ equity | |||||||||||||||||||||||
| convertible preferred units and stock: | |||||||||||||||||||||||
| series a convertible preferred units, no par value, net of issuance costs; no units authorized, issued and outstanding at december 31, 2019; 103,000,000 units authorized; 63,600,000 units issued and outstanding at december 31, 2018. | |||||||||||||||||||||||
| stockholders’ (deficit) equity: | |||||||||||||||||||||||
| junior series a convertible preferred units, no par value; no units authorized, issued or outstanding at december 31, 2019; 6,437,500 units authorized, issued and outstanding at december 31, 2018. | |||||||||||||||||||||||
| common units, no par value; no units authorized, issued or outstanding at december 31, 2019; 195,638 units authorized, issued and outstanding at december 31, 2018. | |||||||||||||||||||||||
| total liabilities, convertible preferred units, stock and stockholders’ equity | 334,831,000 | ||||||||||||||||||||||
| investment in vie | 999,000 | ||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ (deficit) equity | |||||||||||||||||||||||
| convertible preferred stock: | |||||||||||||||||||||||
| series a convertible preferred stock, 0.0001 par value; no shares authorized, | |||||||||||||||||||||||
| issued or outstanding at september 30, 2019 and december 31, 2018, | |||||||||||||||||||||||
| respectively. | |||||||||||||||||||||||
| series a convertible preferred units, no par value, net of issuance costs; | |||||||||||||||||||||||
| no units authorized, issued and outstanding at september 30, 2019; | |||||||||||||||||||||||
| 103,000,000 units authorized; 63,600,000 units issued and outstanding | |||||||||||||||||||||||
| at december 31, 2018. | |||||||||||||||||||||||
| stockholders' (deficit) equity: | |||||||||||||||||||||||
| junior series a convertible preferred stock, no par value; no shares authorized, | |||||||||||||||||||||||
| junior series a convertible preferred units, no par value; | |||||||||||||||||||||||
| no units authorized, issued or outstanding at september 30, 2019; | |||||||||||||||||||||||
| 6,437,500 units authorized, issued and outstanding at december 31, 2018. | |||||||||||||||||||||||
| 43,233,387 shares issued and outstanding, at september 30, 2019; | |||||||||||||||||||||||
| no shares authorized, issued or outstanding at december 31, 2018. | 4,000 | ||||||||||||||||||||||
| common units, no par value; no units authorized, issued or outstanding | |||||||||||||||||||||||
| at september 30, 2019; 195,638 units authorized, issued and outstanding at | |||||||||||||||||||||||
| december 31, 2018. | |||||||||||||||||||||||
| total stockholders’ (deficit) equity | 337,319,000 | ||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ (deficit) equity | 348,395,000 |
We provide you with 20 years of balance sheets for SpringWorks Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of SpringWorks Therapeutics. Explore the full financial landscape of SpringWorks Therapeutics stock with our expertly curated balance sheets.
The information provided in this report about SpringWorks Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.